查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1722870

病毒载体製造市场规模、份额、趋势及预测（按类型、疾病、应用、最终用户和地区），2025 年至 2033 年

Viral Vector Manufacturing Market Size, Share, Trends and Forecast by Type, Disease, Application, End User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球病毒载体製造市场规模价值 14.696 亿美元。展望未来， IMARC Group估计到 2033 年市场规模将达到 85.122 亿美元，2025 年至 2033 年的复合年增长率为 21.6%。北美目前占据市场主导地位，2024 年的市占率将超过 49.3%。遗传疾病盛行率的上升、基因疗法的采用率的提高、先进的生物技术基础设施、不断扩大的临床试验、强大的政府资金、强劲的研发投资以及领先製药公司的存在推动了北美病毒载体製造市场的发展。

病毒载体是分子生物学家用来将遗传物质运送到细胞的工具。它用于替代缺陷基因以治疗遗传疾病，并透过模仿自然感染来表达和呈现致病抗原以产生免疫反应。它广泛用于溶瘤疗法以靶向和杀死肿瘤细胞。除此之外，由于它有助于治疗不同的疾病，如心臟缺陷、代谢疾病和神经退化性疾病，因此它在生命科学研究、基因治疗和疫苗学中得到广泛的应用。目前，由于体内基因突变和染色体受损导致的遗传疾病的盛行率不断上升，病毒载体的生产也在增加。

病毒载体製造市场趋势：

由于人们饮酒量增加和久坐不动的生活方式导致癌症患者增加是推动市场成长的关键因素之一。此外，全球范围内针对病毒载体进行的临床研究数量也在增加。这一点，加上病毒载体在新型药物传输中的日益广泛的应用，正在对市场产生积极的影响。除此之外，它们也是病毒禁用序列的有效载体，并用于将抑制爱滋病毒的转基因递送至人类造血干细胞（HSC）。此外，一些国家的政府正在发起活动，提高人们对病毒载体疫苗的认识。他们也透过快速审批流程等变革来改善监管环境。此外，主要市场参与者正在全球大力投资扩大製造活动的产能。这些参与者也热衷于併购（M&A），预计这将增加他们的整体销售额和获利能力。

本报告回答的关键问题

  • 什么是病毒载体製造？全球病毒载体製造市场有多大？
  • 2025-2033年全球病毒载体製造市场的预期成长率是多少？
  • 推动全球病毒载体製造市场的关键因素有哪些？
  • 根据类型，全球病毒载体製造市场的主要部分是什么？
  • 根据疾病，全球病毒载体製造市场的主要部分是什么？
  • 根据应用，全球病毒载体製造市场的领导部分是什么？
  • 全球病毒载体製造市场的关键区域有哪些？
  • 全球病毒载体製造市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球病毒载体製造市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 腺病毒载体
  • 腺相关病毒载体
  • 慢病毒载体
  • 逆转录病毒载体
  • 其他的

第七章：市场区隔：依疾病

  • 癌症
  • 遗传性疾病
  • 传染病
  • 其他的

第 8 章：市场区隔：按应用

  • 基因治疗
  • 疫苗学

第九章：市场区隔：依最终用户

  • 製药和生物製药公司
  • 研究机构

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Cognate BioServices Inc. (Charles River Laboratories International Inc.)
    • F. Hoffmann-La Roche AG
    • FinVector Oy
    • FUJIFILM Holdings Corporation
    • Kaneka Eurogentec SA (Kaneka Corporation)
    • Lonza Group AG
    • Merck KGaA
    • Oxford Biomedica plc
    • REGENXBIO Inc.
    • Sanofi SA
    • Thermo Fisher Scientific Inc.
    • uniQure NV
Product Code: SR112025A5016

The global viral vector manufacturing market size was valued at USD 1,469.6 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 8,512.2 Million by 2033, exhibiting a CAGR of 21.6% from 2025-2033. North America currently dominates the market, holding a market share of over 49.3% in 2024. The rising prevalence of genetic disorders, increasing adoption of gene therapies, advanced biotechnology infrastructure, expanding clinical trials, strong government funding, robust R&D investments, and the presence of leading pharmaceutical companies drive the viral vector manufacturing market in North America.

A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.

Viral Vector Manufacturing Market Trends:

The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.

Key Market Segmentation:

Breakup by Type:

  • Adenoviral Vectors
  • Adeno-associated Viral Vectors
  • Lentiviral Vectors
  • Retroviral Vectors
  • Others

Breakup by Disease:

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Breakup by Application:

  • Gene Therapy
  • Vaccinology

Breakup by End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Key Questions Answered in This Report

  • 1.What is viral vector manufacturing?
  • 2.How big is the global viral vector manufacturing market?
  • 3.What is the expected growth rate of the global viral vector manufacturing market during 2025-2033?
  • 4.What are the key factors driving the global viral vector manufacturing market?
  • 5.What is the leading segment of the global viral vector manufacturing market based on type?
  • 6.What is the leading segment of the global viral vector manufacturing market based on disease?
  • 7.What is the leading segment of the global viral vector manufacturing market based on application?
  • 8.What are the key regions in the global viral vector manufacturing market?
  • 9.Who are the key players/companies in the global viral vector manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Viral Vector Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Adenoviral Vectors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Adeno-associated Viral Vectors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Lentiviral Vectors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Retroviral Vectors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Genetic Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Gene Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Vaccinology
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical and Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Cognate BioServices Inc. (Charles River Laboratories International Inc.)
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 F. Hoffmann-La Roche AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 FinVector Oy
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 FUJIFILM Holdings Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Kaneka Eurogentec S.A. (Kaneka Corporation)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Lonza Group AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Oxford Biomedica plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 REGENXBIO Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 uniQure N.V.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials

List of Figures

  • Figure 1: Global: Viral Vector Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Viral Vector Manufacturing Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Viral Vector Manufacturing Market: Breakup by Disease (in %), 2024
  • Figure 6: Global: Viral Vector Manufacturing Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Viral Vector Manufacturing Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Viral Vector Manufacturing Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Viral Vector Manufacturing (Retroviral Vectors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Viral Vector Manufacturing (Retroviral Vectors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Viral Vector Manufacturing (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Viral Vector Manufacturing (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Viral Vector Manufacturing (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Viral Vector Manufacturing (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Viral Vector Manufacturing (Genetic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Viral Vector Manufacturing (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Viral Vector Manufacturing (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Viral Vector Manufacturing (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Viral Vector Manufacturing (Other Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Viral Vector Manufacturing (Other Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Viral Vector Manufacturing (Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Viral Vector Manufacturing (Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Viral Vector Manufacturing (Vaccinology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Viral Vector Manufacturing (Vaccinology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Viral Vector Manufacturing (Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Viral Vector Manufacturing (Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia-Pacific: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia-Pacific: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Viral Vector Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Viral Vector Manufacturing Market: Breakup by Country (in %), 2024
  • Figure 83: Middle East and Africa: Viral Vector Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Global: Viral Vector Manufacturing Industry: SWOT Analysis
  • Figure 85: Global: Viral Vector Manufacturing Industry: Value Chain Analysis
  • Figure 86: Global: Viral Vector Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Viral Vector Manufacturing Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Viral Vector Manufacturing Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Viral Vector Manufacturing Market Forecast: Breakup by Disease (in Million USD), 2025-2033
  • Table 4: Global: Viral Vector Manufacturing Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Viral Vector Manufacturing Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Viral Vector Manufacturing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Viral Vector Manufacturing Market: Competitive Structure
  • Table 8: Global: Viral Vector Manufacturing Market: Key Players